Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with theKRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Addiction | Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Smokers | Study